CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 94 filers reported holding CUE BIOPHARMA INC in Q3 2020. The put-call ratio across all filers is 0.71 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $4,112,122 | -21.6% | 1,151,855 | -37.4% | 1.95% | -31.9% |
| Q4 2022 | $5,245,454 | +52.2% | 1,840,510 | +19.1% | 2.86% | +54.9% |
| Q3 2022 | $3,447,000 | -16.4% | 1,545,573 | -6.6% | 1.85% | -43.1% |
| Q2 2022 | $4,122,000 | -44.1% | 1,655,477 | +9.6% | 3.25% | -31.8% |
| Q1 2022 | $7,370,000 | -21.4% | 1,510,282 | +82.2% | 4.76% | -15.2% |
| Q4 2021 | $9,376,000 | -1.8% | 829,042 | +26.5% | 5.61% | +6.9% |
| Q3 2021 | $9,546,000 | +30.0% | 655,185 | +3.9% | 5.25% | +14.4% |
| Q2 2021 | $7,344,000 | +8.1% | 630,364 | +13.2% | 4.59% | -17.4% |
| Q1 2021 | $6,793,000 | -40.1% | 556,777 | -38.6% | 5.56% | +6.1% |
| Q4 2020 | $11,341,000 | +6.1% | 906,569 | +27.7% | 5.24% | +3.1% |
| Q3 2020 | $10,685,000 | +40.5% | 709,936 | +128.8% | 5.08% | +55.7% |
| Q2 2020 | $7,605,000 | -2.9% | 310,294 | -43.8% | 3.26% | -10.9% |
| Q1 2020 | $7,834,000 | +258.5% | 552,060 | +301.1% | 3.66% | +281.9% |
| Q4 2019 | $2,185,000 | – | 137,628 | – | 0.96% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 1,510,282 | $7,370,000 | 4.76% |
| SANDERS MORRIS HARRIS LLC | 873,021 | $4,261,000 | 0.83% |
| P.A.W. CAPITAL CORP | 150,000 | $732,000 | 0.76% |
| Nantahala Capital Management | 2,244,359 | $10,952,000 | 0.48% |
| Bleichroeder LP | 552,000 | $2,694,000 | 0.48% |
| APOGEM CAPITAL LLC | 111,259 | $543,000 | 0.37% |
| Slate Path Capital LP | 1,483,619 | $7,240,000 | 0.37% |
| Robertson Stephens Wealth Management, LLC | 478,500 | $2,335,000 | 0.20% |
| CARLSON CAPITAL L P | 405,000 | $1,976,000 | 0.14% |
| Bridgefront Capital, LLC | 19,968 | $97,000 | 0.12% |